SCHEMBL5841241

SCHEMBL5841241

COC(=O)c1cc(Sc2ccoc2C)c([N+](=O)[O-])s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 2/20 0.41
SELE P16581 2/20 0.41
ALDH1A1 P00352 7/20 0.37
HPGD P15428 3/20 0.37
USP10 Q14694 1/20 0.36
VCAM1 P19320 2/20 0.35
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 4/20 0.34
HSD17B10 Q99714 3/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 3/20 0.33
GAA P10253 1/20 0.33
NPC1 O15118 1/20 0.32
MEN1 O00255 1/20 0.32
TP53 P04637 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5840639 0.78 MAPT (0.41) ALDH1A1HPGDKMT2AKDM4ERAB9A
SCHEMBL5839296 0.75 ALDH1A1 (0.43) ICAM1SELEALDH1A1HPGDUSP10
SCHEMBL5840563 0.74 EDNRA (0.43) ICAM1SELEALDH1A1VCAM1KMT2A
SCHEMBL5841470 0.74 ICAM1 (0.39) ICAM1SELEALDH1A1HPGDUSP10
SCHEMBL8363261 0.72 USP10 (0.42) ALDH1A1HPGDUSP10VCAM1KMT2A
SCHEMBL5841158 0.72 ICAM1 (0.40) ICAM1SELEALDH1A1HPGDVCAM1
SCHEMBL5840567 0.71 XDH (0.41) ICAM1SELEALDH1A1HPGDUSP10
SCHEMBL5841225 0.70 ICAM1 (0.43) ICAM1SELEHPGDVCAM1KMT2A
SCHEMBL31330200 0.69 COMT (0.42) ALDH1A1HPGDUSP10VCAM1KMT2A
SCHEMBL5840709 0.69 PTPN2 (0.39) ALDH1A1HPGDUSP10VCAM1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ICAM1 3438/4885SELE 181/4885ALDH1A1 3674/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R ICAM1 3387/4885SELE 331/4885ALDH1A1 2779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.